Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)
- Conditions
- HIV Infections
- Interventions
- Registration Number
- NCT00054717
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
Demonstrate the safety and efficacy of Tipranavir/Ritonavir versus an active treatment regimen in highly treatment experienced Human Immunodeficiency virus 1(HIV-1) infected patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 630
Patients meeting the following criteria will be eligible for participation in th is study:
- Human Immunodeficiency virus 1 (HIV-1) infected males or females >=18 years of age.
- Screening genotypic resistance report indicating both of the following: at least one primary protease Inhibitor (PI) mutation at the following sites:
30N, 46I/L, 48V, 50V, 82A/F/L/T, 84V or 90M, and no more than two protease mutations on codons 33, 82, 84, or 90.
-
At least 3 consecutive months experience taking antiretrovirals (ARVs) from each of the classes of nucleoside reverse transcriptase inhibitors(NRTI(s)), non-nucleoside reverse transcriptase inhibitors(NNRTI(s)), and protease inhibitors (PIs) at some point in treatment history,with at least 2 protease inhibitor (PI)-based regimens, one of which must be the current regimen, and current protease inhibitor (PI)-based antiretroviral (ARV) medication regimen for at least 3 months prior to randomization.
-
Human Immunodeficiency Virus 1 (HIV-1) viral load >=1,000 copies/mL at screening.
Exclusion criteria:
Patients with any of the following criteria are excluded from participation in t he study:
- Antiretroviral (ARV) medication naïve.
- Patients on recent drug holiday, defined as off antiretroviral (ARV) medications for at least 7 consecutive days within the last 3 months.
- alanine aminotransferase (ALT) >=3.0x upper limit of normal (ULN) and aspartate aminotransferase(AST) >=2.5x upper limit of normal (ULN) (>=Division of AIDS(DAIDS) Grade 1) at either screening visit.
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Tipranavir(TPV)/low dose ritonavir(r) Ritonavir(r) - Tipranavir(TPV)/low dose ritonavir(r) Tipranavir - Comparator protease inhibitor(CPI)/low dose ritonavir(r) Ritonavir(r) - Comparator protease inhibitor(CPI)/low dose ritonavir(r) Comparator Protease Inhibitor (CPI) -
- Primary Outcome Measures
Name Time Method Treatment Response at Week 48 At week 48 Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound
Time to Treatment Failure Through 48 Weeks of Treatment Week 48 Time to treatment failure is defined as 0 for patients who never achieve TR otherwise time to treatment failure is the earliest time of death, discontinuation of the study drug or introduction of a new anti-retroviral drug to the regimen if it is not solely related to either toxicity or intolerance clearly attributable to a background, or the first of two consecutive visits with VL measurements \<1 log10 below baseline.
- Secondary Outcome Measures
Name Time Method Mean Change From Baseline to Week 24 in CD4+ Cell Count Baseline to Week 24 Mean Change From Baseline to Week 32 in CD4+ Cell Count Baseline to Week 32 Mean Change From Baseline to Week 88 in CD4+ Cell Count Baseline to Week 88 Virologic Response (VL < 400 Copies/ml) at Viral Load Nadir, LOCF Week 2 through Week 96 (at any point during trial) Percentage of participants with Viral Load \< 400 copies/mL
Virologic Response (VL < 400 Copies/ml) at Week 16 Week 16 Percentage of participants with Viral Load \< 400 copies/mL
Mean Change From Baseline to Week 40 in CD4+ Cell Count Baseline to Week 40 Mean Change From Baseline to Week 48 in CD4+ Cell Count Baseline to Week 48 Mean Change From Baseline to Week 56 in CD4+ Cell Count Baseline to Week 56 Mean Change From Baseline to Week 64 in CD4+ Cell Count Baseline to Week 64 Mean Change From Baseline to Week 72 in CD4+ Cell Count Baseline to Week 72 Mean Change From Baseline to Week 80 in CD4+ Cell Count Baseline to Week 80 Virologic Response (VL < 400 Copies/ml) at Week 72 Week 72 Percentage of participants with Viral Load \< 400 copies/mL
Virologic Response (VL < 400 Copies/ml) at Week 80 Week 80 Percentage of participants with Viral Load \< 400 copies/mL
Virologic Response (VL < 400 Copies/ml) at Week 88 week 88 Percentage of participants with Viral Load \< 400 copies/mL
Treatment Response at Week 24 Week 24 Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound
Treatment Response at Week 2 week 2 Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound
Treatment Response at Week 4 week 4 Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound
Treatment Response at Week 8 week 8 Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound
Treatment Response at Week 16 week 16 Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound
Treatment Response at Week 32 Week 32 Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound
Treatment Response at Week 40 Week 40 Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound
Treatment Response at Week 48 Week 48 Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound
Treatment Response at Week 56 week 56 Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound
Treatment Response at Week 64 week 64 Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound
Virologic Response (VL < 400 Copies/ml) at Week 24 Week 24 Percentage of participants with Viral Load \< 400 copies/mL
Virologic Response (VL < 400 Copies/ml) at Week 32 week 32 Percentage of participants with Viral Load \< 400 copies/mL
Virologic Response (VL < 400 Copies/ml) at Week 40 Week 40 Percentage of participants with Viral Load \< 400 copies/mL
Treatment Response at Week 72 Week 72 Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound
Treatment Response at Week 80 Week 80 Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound
Treatment Response at Week 88 Week 88 Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound
Mean Change From Baseline to Week 96 in CD4+ Cell Count Baseline to Week 96 Virologic Response (VL < 400 Copies/ml) at Week 48 Week 48 Percentage of participants with Viral Load \< 400 copies/mL
Virologic Response (VL < 400 Copies/ml) at Week 56 Week 56 Percentage of participants with Viral Load \< 400 copies/mL
Virologic Response (VL < 400 Copies/ml) at Week 64 Week 64 Percentage of participants with Viral Load \< 400 copies/mL
Treatment Response at Week 96 Week 96 Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound
Time to Treatment Failure Through 96 Weeks of Treatment Week 96 time to treatment failure is defined as 0 for patients who never achieve TR otherwise time to treatment failure is the earliest time of death, discontinuation of the study drug or introduction of a new anti-retroviral drug to the regimen if it is not solely related to either toxicity or intolerance clearly attributable to a background, or the first of two consecutive visits with VL measurements \<1 log10 below baseline.
Time to Confirmed Virologic Failure Through 48 Weeks of Treatment Week 48 Time to virologic failure is defined as the time from the start of treatment to the last measurement with a viral load reduction greater than 1.0 log before a confirmed drop of viral load reduction below 1.0 log.
Time to Confirmed Virologic Failure Through 96 Weeks of Treatment Week 96 Time to virologic failure is defined as the time from the start of treatment to the last measurement with a viral load reduction greater than 1.0 log before a confirmed drop of viral load reduction below 1.0 log.
Virologic Response (Viral Load >= 1 Log Drop) at Viral Load Nadir, LOCF Week 2 through Week 96 (at any point during trial) Percentage of participants with Viral Load (VL) \>= 1 log reduction from baseline
Virologic Response (Viral Load >= 1 Log Drop) at Week 2 Week 2 Percentage of participants with Viral Load (VL) \>= 1 log reduction from baseline
Virologic Response (Viral Load >= 1 Log Drop) at Week 4 Week 4 Percentage of participants with Viral Load (VL) \>= 1 log reduction from baseline
Virologic Response (Viral Load >= 1 Log Drop) at Week 8 Week 8 Percentage of participants with Viral Load (VL) \>= 1 log reduction from baseline
Virologic Response (Viral Load >= 1 Log Drop) at Week 16 Week 16 Percentage of participants with Viral Load (VL) \>= 1 log reduction from baseline
Virologic Response (Viral Load >= 1 Log Drop) at Week 24 Week 24 Percentage of participants with Viral Load (VL) \>= 1 log reduction from baseline
Virologic Response (Viral Load >= 1 Log Drop) at Week 32 Week 32 Percentage of participants with Viral Load (VL) \>= 1 log reduction from baseline
Virologic Response (Viral Load >= 1 Log Drop) at Week 40 Week 40 Percentage of participants with Viral Load (VL) \>= 1 log reduction from baseline
Virologic Response (Viral Load >= 1 Log Drop) at Week 48 Week 48 Percentage of participants with Viral Load (VL) \>= 1 log reduction from baseline
Virologic Response (Viral Load >= 1 Log Drop) at Week 56 Week 56 Percentage of participants with Viral Load (VL) \>= 1 log reduction from baseline
Virologic Response (Viral Load >= 1 Log Drop) at Week 64 Week 64 Percentage of participants with Viral Load (VL) \>= 1 log reduction from baseline
Median Change From Baseline in Viral Load to Week 2 Baseline to Week 2 Median Change From Baseline in Viral Load to Week 4 Baseline to Week 4 Median Change From Baseline in Viral Load to Week 8 Baseline to Week 8 Median Change From Baseline in Viral Load to Week 16 Baseline to Week 16 Median Change From Baseline in Viral Load to Week 24 Baseline to Week 24 Median Change From Baseline in Viral Load to Week 32 Baseline to Week 32 Median Change From Baseline in Viral Load to Week 40 Baseline to Week 40 Median Change From Baseline in Viral Load to Week 48 Baseline to Week 48 Median Change From Baseline in Viral Load to Week 56 Baseline to Week 56 Median Change From Baseline in Viral Load to Week 64 Baseline to Week 64 Median Change From Baseline in Viral Load to Week 72 Baseline to Week 72 Median Change From Baseline in Viral Load to Week 80 Baseline to Week 80 Median Change From Baseline in Viral Load to Week 88 Baseline to Week 88 Median Change From Baseline in Viral Load to Week 96 Baseline to Week 96 Mean Change From Baseline to Week 2 in CD4+ Cell Count Baseline to Week 2 Mean Change From Baseline to Week 4 in CD4+ Cell Count Baseline to Week 4 Mean Change From Baseline to Week 8 in CD4+ Cell Count Baseline to Week 8 Mean Change From Baseline to Week 16 in CD4+ Cell Count Baseline to Week 16 Time to New CDC Class C Progression Event or Death. after 48 weeks of treatment Time to new Centers for Disease Control and Prevention (CDC) class C progression event (i.e., new AIDS defining illness) or death
Virologic Response (VL < 400 Copies/ml) at Week 2 Week 2 Percentage of participants with Viral Load \< 400 copies/mL
Virologic Response (VL < 400 Copies/ml) at Week 4 Week 4 Percentage of participants with Viral Load \< 400 copies/mL
Virologic Response (VL < 400 Copies/ml) at Week 8 Week 8 Percentage of participants with Viral Load \< 400 copies/mL
Virologic Response (VL < 400 Copies/ml) at Week 96 week 96 Percentage of participants with Viral Load \< 400 copies/mL
Virologic Response (VL < 50 Copies/ml) at Viral Load Nadir, LOCF Week 2 through Week 96 (at any point during trial) Percentage of participants with Viral Load \< 50 copies/mL
Virologic Response (VL < 50 Copies/ml) at Week 32 Week 32 Percentage of participants with Viral Load \< 50 copies/mL
Virologic Response (VL < 50 Copies/ml) at Week 40 Week 40 Percentage of participants with Viral Load \< 50 copies/mL
Virologic Response (VL < 50 Copies/ml) at Week 48 Week 48 Percentage of participants with Viral Load \< 50 copies/mL
Virologic Response (VL < 50 Copies/ml) at Week 56 Week 56 Percentage of participants with Viral Load \< 50 copies/mL
Virologic Response (VL < 50 Copies/ml) at Week 64 Week 64 Percentage of participants with Viral Load \< 50 copies/mL
Virologic Response (VL < 50 Copies/ml) at Week 72 Week 72 Percentage of participants with Viral Load \< 50 copies/mL
Virologic Response (VL < 50 Copies/ml) at Week 80 Week 80 Percentage of participants with Viral Load \< 50 copies/mL
Virologic Response (VL < 50 Copies/ml) at Week 88 Week 88 Percentage of participants with Viral Load \< 50 copies/mL
Virologic Response (VL < 50 Copies/ml) at Week 96 Week 96 Percentage of participants with Viral Load \< 50 copies/mL
Percentage of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 Laboratory Abnormalities 240 Weeks NIH Division of Acquired Immunodeficiency Syndrome (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
Virologic Response (VL < 50 Copies/ml) at Week 2 Week 2 Percentage of participants with Viral Load \< 50 copies/mL
Virologic Response (VL < 50 Copies/ml) at Week 4 Week 4 Percentage of participants with Viral Load \< 50 copies/mL
Virologic Response (VL < 50 Copies/ml) at Week 8 Week 8 Percentage of participants with Viral Load \< 50 copies/mL
Virologic Response (VL < 50 Copies/ml) at Week 16 Week 16 Percentage of participants with Viral Load \< 50 copies/mL
Virologic Response (VL < 50 Copies/ml) at Week 24 Week 24 Percentage of participants with Viral Load \< 50 copies/mL
Trial Locations
- Locations (117)
1182.12.9 Boehringer Ingelheim Investigational Site
🇺🇸Berkeley, California, United States
1182.12.7 Boehringer Ingelheim Investigational Site
🇺🇸Norwalk, Connecticut, United States
1182.12.1 Boehringer Ingelheim Investigational Site
🇺🇸Los Angeles, California, United States
1182.12.123 Infectious Disease Clinics of Emory
🇺🇸Atlanta, Georgia, United States
1182.12.28 University of Pennsylvania
🇺🇸Philadelphia, Pennsylvania, United States
1182.12.100 Boehringer Ingelheim Investigational Site
🇺🇸Boston, Massachusetts, United States
1182.12.41 Boehringer Ingelheim Investigational Site
🇺🇸Boston, Massachusetts, United States
1182.12.99 Boehringer Ingelheim Investigational Site
🇺🇸San Diego, California, United States
1182.12.24 Boehringer Ingelheim Investigational Site
🇺🇸Cincinnati, Ohio, United States
1182.12.11002 Boehringer Ingelheim Investigational Site
🇨🇦Vancouver, British Columbia, Canada
1182.12.62 Boehringer Ingelheim Investigational Site
🇺🇸Phoenix, Arizona, United States
1182.12.25 Boehringer Ingelheim Investigational Site
🇺🇸San Francisco, California, United States
1182.12.53 Boehringer Ingelheim Investigational Site
🇺🇸San Francisco, California, United States
1182.12.98 University of Colorado Health Sciences Center
🇺🇸Denver, Colorado, United States
1182.12.5 Boehringer Ingelheim Investigational Site
🇺🇸San Francisco, California, United States
1182.12.54 Boehringer Ingelheim Investigational Site
🇺🇸Detroit, Michigan, United States
1182.12.80 Infectious Disease Institute Clinical Trials Unit
🇺🇸Oklahoma City, Oklahoma, United States
1182.12.63 Boehringer Ingelheim Investigational Site
🇺🇸Tampa, Florida, United States
1182.12.6 Boehringer Ingelheim Investigational Site
🇺🇸Bethesda, Maryland, United States
1182.12.52 Boehringer Ingelheim Investigational Site
🇺🇸Washington, District of Columbia, United States
1182.12.69 UC Davis Medical Center
🇺🇸Sacramento, California, United States
1182.12.23 Boehringer Ingelheim Investigational Site
🇺🇸Beverly Hills, California, United States
1182.12.108 El Rio SIA
🇺🇸Tucson, Arizona, United States
1182.12.82 Boehringer Ingelheim Investigational Site
🇺🇸Los Angeles, California, United States
1182.12.12 Boehringer Ingelheim Investigational Site
🇺🇸Fountain Valley, California, United States
1182.12.59 David Geffen School of Medicine at UCLA
🇺🇸Los Angeles, California, United States
1182.12.97 Boehringer Ingelheim Investigational Site
🇺🇸Los Angeles, California, United States
1182.12.89 Boehringer Ingelheim Investigational Site
🇺🇸San Diego, California, United States
1182.12.103 Boehringer Ingelheim Investigational Site
🇺🇸Washington, District of Columbia, United States
1182.12.70
🇺🇸Washington, District of Columbia, United States
1182.12.79 Boehringer Ingelheim Investigational Site
🇺🇸Fort Lauderdale, Florida, United States
1182.12.77 Boehringer Ingelheim Investigational Site
🇺🇸Fort Myers, Florida, United States
1182.12.45 Boehringer Ingelheim Investigational Site
🇺🇸Miami, Florida, United States
1182.12.93 Boehringer Ingelheim Investigational Site
🇺🇸Miami Beach, Florida, United States
1182.12.17 Boehringer Ingelheim Investigational Site
🇺🇸Orlando, Florida, United States
1182.12.85 Boehringer Ingelheim Investigational Site
🇺🇸Miami, Florida, United States
1182.12.90 Boehringer Ingelheim Investigational Site
🇺🇸Sarasota, Florida, United States
1182.12.78 Boehringer Ingelheim Investigational Site
🇺🇸Tampa, Florida, United States
1182.12.67 Boehringer Ingelheim Investigational Site
🇺🇸Vero Beach, Florida, United States
1182.12.88 Boehringer Ingelheim Investigational Site
🇺🇸Atlanta, Georgia, United States
1182.12.72 Boehringer Ingelheim Investigational Site
🇺🇸Decatur, Georgia, United States
1182.12.47 Boehringer Ingelheim Investigational Site
🇺🇸Macon, Georgia, United States
1182.12.8 Family Practice Medical Center
🇺🇸Boise, Idaho, United States
1182.12.105 Boehringer Ingelheim Investigational Site
🇺🇸Chicago, Illinois, United States
1182.12.3 Boehringer Ingelheim Investigational Site
🇺🇸Chicago, Illinois, United States
1182.12.49 Boehringer Ingelheim Investigational Site
🇺🇸Chicago, Illinois, United States
1182.12.32 Boehringer Ingelheim Investigational Site
🇺🇸Indianapolis, Indiana, United States
1182.12.48 Boehringer Ingelheim Investigational Site
🇺🇸Indianapolis, Indiana, United States
1182.12.33 Boehringer Ingelheim Investigational Site
🇺🇸Lexington, Kentucky, United States
1182.12.44 Boehringer Ingelheim Investigational Site
🇺🇸Louisville, Kentucky, United States
1182.12.81 Boehringer Ingelheim Investigational Site
🇺🇸Portland, Maine, United States
1182.12.30 Boehringer Ingelheim Investigational Site
🇺🇸Baltimore, Maryland, United States
1182.12.101 Boehringer Ingelheim Investigational Site
🇺🇸Boston, Massachusetts, United States
1182.12.61 Boehringer Ingelheim Investigational Site
🇺🇸Springfield, Massachusetts, United States
1182.12.13 University of Michigan Health System
🇺🇸Ann Arbor, Michigan, United States
1182.12.14 Dybedal Center for Clinical Research
🇺🇸Kansas City, Missouri, United States
1182.12.120 Department of Medicine, HIV/AIDS Program
🇺🇸Minneapolis, Minnesota, United States
1182.12.56 Boehringer Ingelheim Investigational Site
🇺🇸Detroit, Michigan, United States
1182.12.11 Wellness Center
🇺🇸Las Vegas, Nevada, United States
1182.12.87 Boehringer Ingelheim Investigational Site
🇺🇸St Louis, Missouri, United States
1182.12.4 Boehringer Ingelheim Investigational Site
🇺🇸Camden, New Jersey, United States
1182.12.68 Boehringer Ingelheim Investigational Site
🇺🇸Albany, New York, United States
1182.12.40 Boehringer Ingelheim Investigational Site
🇺🇸Santa Fe, New Mexico, United States
1182.12.34 Boehringer Ingelheim Investigational Site
🇺🇸Mount Vernon, New York, United States
1182.12.119 Boehringer Ingelheim Investigational Site
🇺🇸New York, New York, United States
1182.12.22 Boehringer Ingelheim Investigational Site
🇺🇸New York, New York, United States
1182.12.36 Boehringer Ingelheim Investigational Site
🇺🇸New York, New York, United States
1182.12.58 Beth Israel Medical Center
🇺🇸New York, New York, United States
1182.12.96 Boehringer Ingelheim Investigational Site
🇺🇸New York, New York, United States
1182.12.43 Boehringer Ingelheim Investigational Site
🇺🇸Valhalla, New York, United States
1182.12.83 Boehringer Ingelheim Investigational Site
🇺🇸Stony Brook, New York, United States
1182.12.42 Boehringer Ingelheim Investigational Site
🇺🇸Durham, North Carolina, United States
1182.12.109 Boehringer Ingelheim Investigational Site
🇺🇸Akron, Ohio, United States
1182.12.46 Boehringer Ingelheim Investigational Site
🇺🇸Huntersville, North Carolina, United States
1182.12.35 Boehringer Ingelheim Investigational Site
🇺🇸Cleveland, Ohio, United States
1182.12.65 Ohio State University Medical Center
🇺🇸Columbus, Ohio, United States
1182.12.114 Pinnacle Health
🇺🇸Harrisburg, Pennsylvania, United States
1182.12.50 Boehringer Ingelheim Investigational Site
🇺🇸Philadelphia, Pennsylvania, United States
1182.12.86 The Miriam Hospital
🇺🇸Providence, Rhode Island, United States
1182.12.10 Boehringer Ingelheim Investigational Site
🇺🇸Columbia, South Carolina, United States
1182.12.116 Greenville Hospital System
🇺🇸Greenville, South Carolina, United States
1182.12.106 Boehringer Ingelheim Investigational Site
🇺🇸Dallas, Texas, United States
1182.12.2 Boehringer Ingelheim Investigational Site
🇺🇸Memphis, Tennessee, United States
1182.12.31 Boehringer Ingelheim Investigational Site
🇺🇸Houston, Texas, United States
1182.12.26 Boehringer Ingelheim Investigational Site
🇺🇸San Antonio, Texas, United States
1182.12.122 VCU Health Systems
🇺🇸Richmond, Virginia, United States
1182.12.15 Boehringer Ingelheim Investigational Site
🇺🇸Seattle, Washington, United States
1182.12.29 Boehringer Ingelheim Investigational Site
🇺🇸Milwaukee, Wisconsin, United States
1182.12.1401 St. Vincent's Hospital
🇦🇺Darlinghurst, New South Wales, Australia
1182.12.1405 AIDS Research Initiative / Ground Zero
🇦🇺Darlinghurst, New South Wales, Australia
1182.12.1407 Holdsworth House General Practice
🇦🇺Darlinghurst, New South Wales, Australia
1182.12.1403 Albion Street Centre
🇦🇺Surry Hills, New South Wales, Australia
1182.12.1406 Gold Coast Sexual Health Clinic
🇦🇺Miami, Queensland, Australia
1182.12.1404 Alfred Hospital
🇦🇺Melbourne, Victoria, Australia
1182.12.11016 Boehringer Ingelheim Investigational Site
🇨🇦Halifax, Nova Scotia, Canada
1182.12.11010 Boehringer Ingelheim Investigational Site
🇨🇦Winnipeg, Manitoba, Canada
1182.12.11012 Boehringer Ingelheim Investigational Site
🇨🇦Hamilton, Ontario, Canada
1182.12.11004 Boehringer Ingelheim Investigational Site
🇨🇦Toronto, Ontario, Canada
1182.12.11006 Boehringer Ingelheim Investigational Site
🇨🇦Toronto, Ontario, Canada
1182.12.11014 Boehringer Ingelheim Investigational Site
🇨🇦Toronto, Ontario, Canada
1182.12.11009 Boehringer Ingelheim Investigational Site
🇨🇦Toronto, Ontario, Canada
1182.12.11015 Boehringer Ingelheim Investigational Site
🇨🇦Monteal, Quebec, Canada
1182.12.11003 Boehringer Ingelheim Investigational Site
🇨🇦Montreal, Quebec, Canada
1182.12.11013 Boehringer Ingelheim Investigational Site
🇨🇦Montreal, Quebec, Canada
1182.12.11007 Boehringer Ingelheim Investigational Site
🇨🇦Montreal, Quebec, Canada
1182.12.60 Boehringer Ingelheim Investigational Site
🇵🇷Santurce, Puerto Rico
1182.12.76 Boehringer Ingelheim Investigational Site
🇺🇸Long Beach, California, United States
1182.12.94 Infectious Disease Research Institute
🇺🇸Tampa, Florida, United States
1182.12.95 Boehringer Ingelheim Investigational Site
🇺🇸New Orleans, Louisiana, United States
1182.12.55 Boehringer Ingelheim Investigational Site
🇺🇸Dallas, Texas, United States
1182.12.73 Boehringer Ingelheim Investigational Site
🇺🇸Houston, Texas, United States
1182.12.1408 407 Doctors Pty Ltd.
🇦🇺Darlinghurst, New South Wales, Australia
1182.12.107 Boehringer Ingelheim Investigational Site
🇺🇸Rochester, New York, United States
1182.12.75 CARES Resource
🇺🇸Miami, Florida, United States
1182.12.11001 Boehringer Ingelheim Investigational Site
🇨🇦Ottawa, Ontario, Canada
1182.12.91 Boehringer Ingelheim Investigational Site
🇺🇸Annandale, Virginia, United States
1182.12.21 Boehringer Ingelheim Investigational Site
🇺🇸East Orange, New Jersey, United States